Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N R Cutler

Showing results (31-40 of 166) with videos related to

Pageof 17
Sort By:
The American Journal of Psychiatry|November 1, 1978
Prediction of self-mutilation in hospitalized schizophrenicsD Shore, D J Anderson, N R Cutler
The Annals of Pharmacotherapy|February 11, 2000
Gender differences in depression and antidepressant pharmacokinetics and adverse eventsE J Frackiewicz, J J Sramek, N R Cutler
Expert Opinion on Investigational Drugs|November 4, 2000
Review of the acetylcholinesterase inhibitor galanthamineJ J Sramek, E J Frackiewicz, N R Cutler
Neurodegeneration : a Journal for Neurodegenerative Disorders, Neuroprotection, and Neuroregeneration|December 1, 1996
The bridging concept: optimizing dose for phase II/III in Alzheimer's diseaseN R Cutler, J J Sramek, J R Kilborn
The Annals of Pharmacotherapy|October 31, 2000
Mild cognitive impairment: emerging therapeuticsJ J Sramek, A E Veroff, N R Cutler
Expert Opinion on Investigational Drugs|April 3, 2001
The status of ongoing trials for mild cognitive impairmentJ J Sramek, A E Veroff, N R Cutler
Archives of Neurology|September 1, 1993
Poor tolerability of MK-458N R Cutler, J J Sramek, G A Block
Progress in Neuro-Psychopharmacology & Biological Psychiatry|May 1, 1994
A phase II multicenter dose-finding, efficacy and safety trial of ipsapirone in outpatients with generalized anxiety disorderN R Cutler, J M Hesselink, J J Sramek
Clinical Therapeutics|May 1, 1997
Efficacy and safety of two dosing regimens of buspirone in the treatment of outpatients with persistent anxietyJ J Sramek, E J Frackiewicz, N R Cutler
The Annals of Pharmacotherapy|May 20, 1999
Cholinesterase inhibitors: a therapeutic strategy for Alzheimer diseaseW J Krall, J J Sramek, N R Cutler
Pageof 17

Showing results (31-40 of 166) with videos related to

Sort By:
Pageof 17
The American Journal of Psychiatry|November 1, 1978
Prediction of self-mutilation in hospitalized schizophrenicsD Shore, D J Anderson, N R Cutler
The Annals of Pharmacotherapy|February 11, 2000
Gender differences in depression and antidepressant pharmacokinetics and adverse eventsE J Frackiewicz, J J Sramek, N R Cutler
Expert Opinion on Investigational Drugs|November 4, 2000
Review of the acetylcholinesterase inhibitor galanthamineJ J Sramek, E J Frackiewicz, N R Cutler
Neurodegeneration : a Journal for Neurodegenerative Disorders, Neuroprotection, and Neuroregeneration|December 1, 1996
The bridging concept: optimizing dose for phase II/III in Alzheimer's diseaseN R Cutler, J J Sramek, J R Kilborn
The Annals of Pharmacotherapy|October 31, 2000
Mild cognitive impairment: emerging therapeuticsJ J Sramek, A E Veroff, N R Cutler
Expert Opinion on Investigational Drugs|April 3, 2001
The status of ongoing trials for mild cognitive impairmentJ J Sramek, A E Veroff, N R Cutler
Archives of Neurology|September 1, 1993
Poor tolerability of MK-458N R Cutler, J J Sramek, G A Block
Progress in Neuro-Psychopharmacology & Biological Psychiatry|May 1, 1994
A phase II multicenter dose-finding, efficacy and safety trial of ipsapirone in outpatients with generalized anxiety disorderN R Cutler, J M Hesselink, J J Sramek
Clinical Therapeutics|May 1, 1997
Efficacy and safety of two dosing regimens of buspirone in the treatment of outpatients with persistent anxietyJ J Sramek, E J Frackiewicz, N R Cutler
The Annals of Pharmacotherapy|May 20, 1999
Cholinesterase inhibitors: a therapeutic strategy for Alzheimer diseaseW J Krall, J J Sramek, N R Cutler
Pageof 17